AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01976104
Drug: avatrombopag (lower baseline platelet count)
RxNorm normalized name: avatrombopag
DrugBank: Avatrombopag (DB11995)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 mg avatrombopag (3 x 20 mg tablets)
Trial: NCT01976104
Drug: avatrombopag (higher baseline platelet count)
RxNorm normalized name: avatrombopag
DrugBank: Avatrombopag (DB11995)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg avatrombopag (2 x 20 mg tablets)
Trial: NCT03331302
Drug: Hyperpolarized Xenon-129 MRI (Experimental)
RxNorm normalized name: xenon-129, hyperpolarized
DrugBank: Xenon (DB13453)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRI ventilation scan of the lung with inhaled contrast agent (hyperpolarized Xenon-129)
Trial: NCT03331302
Drug: Radioactive Xenon-133 scintigraphy (Active Comparator)
DrugBank: Xenon-133 (DB09315)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radioactive ventilation scintigraphy of the lung with inhaled radioactive contrast agent (Xenon-133)
Trial: NCT02325206
Drug: dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: one administration in the morning
Trial: NCT01032889
Drug: Deoxycholic acid injection
RxNorm normalized name: deoxycholic acid Injection
DrugBank: Deoxycholic acid (DB03619)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03204006
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine preinduction
Trial: NCT02208427
Drug: Rifapentine and Isoniazid for 3 months
RxNorm normalized name: Rifapentine
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: weekly oral Rifapentine 15 mg/kg plus Isoniazid 15 mg/kg for 12 doses
Trial: NCT02208427
Drug: Isoniazid for 9 months
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: daily oral Isoniazid 5 mg/kg for 9 months under supervision (conventional IPT)
Trial: NCT00850421
Drug: Botulinum Toxin Type A
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: 100 Units - Dilution: 25U/ml (4:1 BOTOX/preservative free saline)
Trial: NCT02949895
Drug: BMS-986012
RxNorm normalized name: BMS-986012
DrugBank: BMS-986012 (DB14831)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02949895
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02949895
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04978103
Drug: Gum Arabic
RxNorm normalized name: Gum arabic
DrugBank: Acacia (DB10451)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A dietary supplement (Powdered exudates of Acacia Senegal (Gum Arabic E-414))
Trial: NCT03497351
Drug: Nicardipine
RxNorm normalized name: Nicardipine
DrugBank: Nicardipine (DB00622)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patients in Group N were infused the 130/0.4 hydroxyethyl starch and sodium chloride injection ( 7 ml/kg, 0.4 ml/kg/min) after anesthesi induction and before skin incision. Then the HR, SAP, DAP, MAP, CO, CI, SV, SVI, PPV and SVV were recorded. When the circulation was stability, Nicardipine was given, and the the 130/0.4 hydroxyethyl starch and sodium chloride injection was infused again.
Trial: NCT03497351
Drug: Urapidil
RxNorm normalized name: urapidil
DrugBank: Urapidil (DB12661)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients in Group N were infused the 130/0.4 hydroxyethyl starch and sodium chloride injection ( 7 ml/kg, 0.4 ml/kg/min) after anesthesi induction and before skin incision. Then the HR, SAP, DAP, MAP, CO, CI, SV, SVI, PPV and SVV were recorded. When the circulation was stability, Urapidil was given, and the the 130/0.4 hydroxyethyl starch and sodium chloride injection was infused again.
Trial: NCT00498004
Drug: Quetiapine, Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The dose of quetiapine will be titrated over 4 days to 300mg/day (50mg at day 1, 100mg at day 2, 200mg at day 3 and 300mg at day 4) and thereafter flexible dose will be administered depending on the clinical state. The dose of risperidone will be titrated as following 2mg at day 1 and 4mg at day 4 and thereafter flexible dose will be administered depending on the clinical state. The dosage of drugs should be 400-800mg/day of quetiapine and 4-6mg/day of risperidone between 6 and 8 weeks of trial.
Trial: NCT04530136
Drug: Ruconest
RxNorm normalized name: Ruconest
DrugBank: Conestat alfa (DB09228)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Patients will be randomized to Ruconest or Standard of Care
Trial: NCT02878798
Drug: topiramate
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral topiramate at a target dose of 50mg twice daily.
Trial: NCT03415711
Drug: Mesalamine
RxNorm normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mesalamine 2.4 g/day in once daily administration.
Trial: NCT03292172
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab will be given intravenously (IV) at a fixed dose of 1200 mg on Day 1 of each cycle, every 3 weeks.
Trial: NCT03292172
Drug: RO6870810
RxNorm normalized name: BET INHIBITOR RO6870810
DrugBank: RO-6870810 (DB15151)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO6870810 will be injected SC,at initial planned doses of 0.30, 0.45, or 0.65 mg/kg, QD for the first 14 days of a 21-day cycle.
Trial: NCT03195309
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Compare different concentration of ropivacaine and fentanyl for elective Cesarean delivery post operative pain control.
Trial: NCT01032109
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: A single intravitreal injection of 1.25 mg of bevacizumab (0.05 mL of solution prepared from Avastin, 100 mg/4 mL vial) was performed within 2 weeks after PDT treatment.
Trial: NCT02978599
Drug: AVL-3288
RxNorm normalized name: AVL-3288
DrugBank: AVL-3288 (DB18707)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily for 5 days
Trial: NCT02507167
Drug: Rifampin
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral rifampin administration (600 mg EREMFAT®)
Trial: NCT03592082
Drug: Bismuth Subsalicylate
RxNorm normalized name: Bismuth Subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BSS 524 mg ((2) 262 mg tablets) given four times per day for 14 days
Trial: NCT01076140
Drug: Nebivolol
RxNorm normalized name: Nebivolol
DrugBank: Nebivolol (DB04861)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebivolol 5 or 10 mg tablets daily for 4 weeks. Lisinopril 20 or 40 mg daily for 4 weeks
Trial: NCT00336648
Drug: Avastin (Bevacizumab)
RxNorm normalized name: Avastin
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10mg/kg by vein (IV) on Days 1, 2, 15 and 29 the adjuvant therapy every two weeks starting approximately 6 weeks after surgery for three months.
Trial: NCT00336648
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg/m2 IV once a week on Days 1, 2, 8,15, 22, 29, 36 +/-2 days (Saturdays)
Trial: NCT00814060
Drug: neratinib
RxNorm normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: HKI-272
Trial: NCT00886678
Drug: pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 500 mg/m2, IV, q 21 days x 2 cycles
Trial: NCT00886678
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: AUC=5,IV,q 21 days x 2 cycles
Trial: NCT01076140
Drug: Lisinopril
RxNorm normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebivolol 5 or 10 mg tablets daily for 4 weeks. Lisinopril 20 or 40 mg daily for 4 weeks
Trial: NCT01920269
Drug: intravesical passive diffusion mitomycin
RxNorm normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A dose of 40 mg mitomycin dissolved in 50 ml sterile water is infused intravesically through a Foley catheter, retained in the bladder for 60 min with catheter clamping, and then drained. Patients who have a complete response to the initial 6 weekly treatments underwent a further 10 monthly instillations, with the same dose and methods of infusion as initial assigned treatment.
Trial: NCT00421746
Drug: Piboserod
RxNorm normalized name: Piboserod
DrugBank: Piboserod (DB04873)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00773201
Drug: Sotalol 80 mg
RxNorm normalized name: sotalol 80 MG
DrugBank: Sotalol (DB00489)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: healthy subjects will receive an unique dose of Sotalol and will have an effort test on ergonomic bicycle, an auditive stimulation and a taking of DNA
Trial: NCT04580992
Drug: Ajmaline
RxNorm normalized name: ajmaline
DrugBank: Ajmaline (DB01426)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ajmaline administration
Trial: NCT03445949
Drug: short postimplantation dual antiplatelet therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: continuing dual antiplatelet therapy up until 6 months after left atrial appendage occlusion with Amplatzer or WATCHMAN device
Trial: NCT03445949
Drug: extended postimplantation dual antiplatelet therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: stopping dual antiplatelet therapy after 30 days after left atrial appendage occlusion with Amplatzer or WATCHMAN device
Trial: NCT03445949
Drug: long-term treatment with a single antiplatelet agent
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: continuing long-term treatment with single antiplatelet agent
Trial: NCT03586570
Drug: Aprocitentan 25mg
RxNorm normalized name: Aprocitentan
DrugBank: Aprocitentan (DB15059)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets in strength of 25 mg
Trial: NCT02703337
Drug: Insulin Lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered SC
Trial: NCT01039103
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone 1 g, IV, infusion over 2 hours on days 1, 2 and 3
Trial: NCT02152917
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00746512
Drug: Prednisone 15 mg
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone 15 mg tablets once daily for 15 days.
Trial: NCT03113500
Drug: Brentuximab Vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03113500
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03113500
Drug: Etoposide Phosphate
RxNorm normalized name: Etoposide Phosphate
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00746512
Drug: Prednisone 7.5 mg
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone 7.5 mg over-encapsulated tablets once daily for 15 days
Trial: NCT04435717
Drug: Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]_#1
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab 20 MG/ML Intravenous (one dose)
Trial: NCT04435717
Drug: Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]_#1 (2 doses)
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab 20 MG/ML Intravenous ( two doses)
Trial: NCT01449799
Drug: Fluticasone Propionate 500 microgram dose
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: To be provided via a combination of 4 inhalers - one 250 microgram fluticasone propionate Diskus inhalation, a second 250 microgram fluticasone proopionate Diskus inhalation, and one inhalation each from two separate placebo Diskus inhalers
Trial: NCT01449799
Drug: GSK961081 800 microgram and Fluticasone Propionate 500 microgram separately
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: To be provided via a combination of 4 inhalers - one 400 microgram GSK961081 Diskus inhalation, a second 400 microgram GSK961081 Diskus inhalation, one 250 microgram fluticasone propionate Diskus inhalation, and a second fluticasone propionate 250 microgram Diskus inhalation
Trial: NCT01449799
Drug: GSK961081 800 microgram Fluticasone Propionate 500 microgram in a blend
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: To be provided via a combination of 4 inhalers - one inhalation of a Diskus inhaler containing a blend of 400 microgram of GSK961081 and 250 microgram of fluticasone propionate per inhalation, a second inhalation of a Diskus inhaler containing a blend of 400 microgram of GSK961081 and 250 microgram of fluticasone propionate per inhalation, and one inhalation each from two separate placebo inhalers
Trial: NCT00781885
Drug: Beraprost sodium modified release
DrugBank: Beraprost (DB05229)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets 60mcg
Trial: NCT00194649
Drug: Miglustat (Zavesca)
RxNorm normalized name: Miglustat
DrugBank: Miglustat (DB00419)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 100 mg Miglustat BID (twice daily) for six weeks
Trial: NCT00003745
Drug: topotecan hydrochloride
RxNorm normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02757417
Drug: sodium fluorescein
RxNorm normalized name: Fluorescein Sodium
DrugBank: Fluorescein (DB00693)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02757417
Drug: phenazopyridine
RxNorm normalized name: Phenazopyridine
DrugBank: Phenazopyridine (DB01438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03113500
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT03699995
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given SC
Trial: NCT03494569
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03494569
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given as per City of Hope Standard Operating Procedure
Trial: NCT02005302
Drug: Vitamin D2
RxNorm normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Vit D2 1.25mg(50,000 unit) once weekly as a start and maintain 1.25mg(50,000 unit) once monthly according to the blood 25(OH)vitamin D level.
Trial: NCT02894268
Drug: Furazolidone
RxNorm normalized name: Furazolidone
DrugBank: Furazolidone (DB00614)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Furazolidone 100mg po bid
Trial: NCT02894268
Drug: Esomeprazole
RxNorm normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Esomeprazole 20mg po bid
Trial: NCT02894268
Drug: Colloidal Bismuth Subcitrate
RxNorm normalized name: Colloidal bismuth subcitrate
DrugBank: Bismuth subcitrate potassium (DB09275)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bismuth 20mg po bid
Trial: NCT01011309
Drug: Sodium stibogluconate
RxNorm normalized name: sodium stibogluconate
DrugBank: Sodium stibogluconate (DB05630)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/kg/day IV daily for 20 days
Trial: NCT00380380
Drug: Vildagliptin
RxNorm normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no
Trial: NCT01085006
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid in cases, normal saline in controls
Trial: NCT02182388
Drug: BI 207127 NA powder for solution
RxNorm normalized name: bis(1-methylamyl) sodium sulfosuccinate
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02182388
Drug: BI 207127 NA tablet
RxNorm normalized name: bis(1-methylamyl) sodium sulfosuccinate
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04154813
Drug: Topiramate
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The initial dose of 25mg/d is rapidly increased to the target dose (100mg/d) or below the maximum tolerable dose if the patient can tolerate it.
Trial: NCT01327066
Drug: Droxidopa
RxNorm normalized name: Droxidopa
DrugBank: Droxidopa (DB06262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 600 mg, single oral dose
Trial: NCT02105662
Drug: Grazoprevir 100 mg/Elbasvir 50 mg fixed-dose combination tablets
DrugBank: Elbasvir (DB11574)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MK-5172A FDC tablet: MK-5172 (100 mg)/MK-8742 (50 mg)
Trial: NCT01327066
Drug: Droxidopa
RxNorm normalized name: Droxidopa
DrugBank: Droxidopa (DB06262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2000 mg, single oral dose
Trial: NCT01327066
Drug: Moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 mg, single oral dose
Trial: NCT00582634
Drug: docetaxel and cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel (75mg/m2) followed by cisplatin (75mg/m2) on day 1 of a 21 day cycle. Both drugs will be administered intravenously over 1 hour each for4 cycles.
Trial: NCT00003182
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003182
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03901352
Drug: Mirogabalin
RxNorm normalized name: mirogabalin
DrugBank: Mirogabalin (DB11825)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Mirogabalin tablets for oral administration
Trial: NCT00229385
Drug: Ziprasidone
RxNorm normalized name: Ziprasidone
DrugBank: Ziprasidone (DB00246)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40-80 mg BID
Trial: NCT00006118
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00006118
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00006118
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01657461
Drug: Intravenous (IV) recombinant human tissue plasminogen activator (rtPA)
RxNorm normalized name: Tissue plasminogen activator, recombinant
DrugBank: Plasminogen (DB16701)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy with Intravenous (IV) recombinant human tissue plasminogen activator (rtPA)
Trial: NCT02641561
Drug: Lactated Ringer's Solution
RxNorm normalized name: Lactated Ringer's Solution Intravenous Solution
DrugBank: Potassium chloride (DB00761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lactated ringer's solution (LR), is an intravenous fluid (IVF) used commonly during endoscopic procedures and operative procedures. It's composition is similar to that of humans including sodium, chloride, potassium, calcium and lactate. Studies have implicated the use of this fluid in pancreatitis treatment and prevention of post-ERCP pancreatitis
Trial: NCT01595399
Drug: atropine
RxNorm normalized name: Atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atropine 0.02 mg/kg IV
Trial: NCT00762073
Drug: budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: oral suspension
Trial: NCT01224769
Drug: bendamustine +/- rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00595946
Drug: Lubiprostone
RxNorm normalized name: Lubiprostone
DrugBank: Lubiprostone (DB01046)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 24 mcg capsules twice daily (BID)
Trial: NCT02334046
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anesthesia was maintained with sevoflurane with 1.5-2.0 vol% in air/50%oxygen mixture, and sevoflurane was adjusted to about 1.0 vol% 10 min before end of surgery.
Trial: NCT03079102
Drug: Nitrogen
RxNorm normalized name: Nitrogen
DrugBank: Nitrogen (DB09152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitrogen is the carrier gas (vehicle) for iNO. Subjects receiving placebo will receive equivalent doses of nitrogen.
Trial: NCT02052492
Drug: EF-022 (Modified Vitamin D Binding Protein Macrophage Activator)
RxNorm normalized name: Klor-Con/EF
DrugBank: EF-022 (DB17768)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02206789
Drug: Prednisolone acetate1%, cyclosporine 2%
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: penetrating keratoplasty--efficacy of prednisolone acetate1%alone versus prednisolone acetate 1%and cyclosporine 2% in preventing graft rejection